Intracellular trafficking of MDR transporters and relevance of SNPs

Current Topics in Medicinal Chemistry

Volumn 9, Issue 2, 2009, Pages 197-208

  Porcelli, Letizia ^a   Lemos, Clara ^b   Peters, Godefridus J ^b   Paradiso, Angelo ^a   Azzariti, Amalia ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BCRP; MDR; MRP; P gP; SNP

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; BREFELDIN A; DAUNORUBICIN; DIFLOMOTECAN; DOXORUBICIN; GEFITINIB; GLYCOPROTEIN P; IMATINIB; IRINOTECAN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN TYROSINE KINASE INHIBITOR; TOPOTECAN;

CANCER PATIENT; CELLULAR DISTRIBUTION; DIARRHEA; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG RETENTION; DRUG TREATMENT FAILURE; DRUG UPTAKE; HUMAN; INTRACELLULAR TRANSPORT; LUNG NON SMALL CELL CANCER; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; HUMANS; MODELS, BIOLOGICAL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 63349112237     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609787521562     Document Type: Review

References (122)

1. Dean, M.; Rzhetsky, A.; Allikmets, R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001, 11, 1156-66a.
2. Szakács, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5, 219-34.
3. Lemos, C.; Kathmann, I.; Giovannetti, E.; Dekker, H.; Scheffer,G. L.; Calhau, C.; Jansen, G.; Peters, G. J. Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells. Int. J. Cancer 2008, 123, 1712-1720.
4. Klein, I.; Sarkadi, B.; and Vaŕadi, A. An inventory of the human ABC proteins. Biochim. Biophys. Acta 1999, 1461, 237-262.
5. Rocchi, E.; Khodjakov, A.; Volk, E. L.; Yang, C. H.; Litman, T.; Bates, S. E.; Schneider, E. The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem. Biophys. Res. Commun. 2000, 271, 42-46.
6. Handschin, C.; Meyer, U. A. Regulatory network of lipid-sensing nuclear receptors: Roles for CAR, PXR, LXR, and FXR. Arch. Biochem. Biophys. 2005, 433, 387-96.
7. Scheffer, G. L.; Maliepaard, M.; Pijnenborg, A. C.; van Gastelen, M. A.; de Jong, M. C.; Schroeijers, A. B.; van der Kolk, D. M.; Allen, J. D.; Ross, D. D.; van der Valk, P.; Dalton, W. S.; Schellens, J. H.; Scheper, R. J. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecanresistant cell lines. Cancer Res. 2000, 60, 2589-93.
8. Xia, C. Q.; Liu, N.; Yang, D.; Miwa, G.; Gan, L. S. Expression, localization, and functional characteristics of breast cancer resistance protein in caco-2 cells. Drug Metab. Dispos. 2005, 33, 637-43.
9. Breuzard, G.; Angiboust, J. F.; Jeannesson, P.; Mainfait, M.; Millot, J. M. Surface enhanced Raman scattering reveals adsorption of mitoxantrone on plasma membrane of living cells. Biochem. Biophys. Res. Commun. 2004, 320, 615-21.
10. Croce, A. C.; Bottiroli, G.; Supino, R.; Favini, E.; Zuco, V.; Zunino, F.; Subcellular localization of the camptothecin analogues, topotecan and gimatecan. Biochem. Pharmacol. 2004, 67(6), 1035-45.
11. Rajagopal, A,; Simon, S. M. Subcellular localization and activity of multidrug resistance proteins. Mol. Biol. Cell. 2003, 14(8), 3389-99.
12. Allen, J. D.; Van Dort, S. C.; Buitelaar, M.; Van Tellingen, O.; Schinkel, A. H. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res. 2003, 63, 1339-44.
13. Jonker, J. W.; Smit, J. W.; Brinkhuis, R. F.; Maliepaard, M.; Beijnen, J. H.; Schellens, J. H. M.; Schinked, A. H. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. 2000, 92, 1651-1656.
14. Maliepaard, M.;. Scheffer, G. L.; Faneyte, I. F.; van Gastelen, M. A.; Pijnenborg, A. C. L. M.; Schinkel, A. H.; van de Vijver, M. J.; Scheper, R. J.; Schellens, J. H. M. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001, 61, 3458-3464.
15. Henriksen, U.; Gether, U.; Litman, T. Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2. J. Cell Sci. 2005, 118, 1417-1426.
16. Kim, H.; Barroso, M.; Samanta, R.; Greenberger, L.; Sztul, E. Experimentally induced changes in the endocytic traffic of P-glycoprotein alter drug resistance of cancer cells Am. J. Physiol. 1997, 273, C687-C702.
17. Storch, C. H.; Ehehalt, R.; Haefeli, W. E.; Weiss, J. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/ caveolae and modulation of its activity by cholesterol in vitro. J. Pharmacol. Exp. Ther. 2007, 323, 257-264.
18. Demeule, M.; Jodoin, J.; Gingras, D.; Beliveau, R. P-glycoprotein is localized in caveole in resistant cells and in brain capillaries. FEBS lett. 2000, 466, 219-224.
19. Hinrichs, J. W.; Klappe, K.; Hummel, I.; Kok J. W. ATP- binding cassette transporters are enriched in non-caveolar detergent-insoluble glycosphingolipid-enriched membrane domains (DIGs) in human multidrug-resistant cancer cells. J. Biol. Chem. 2004, 279, 5734-5738.
20. Gayet, L.; Dayan, G.; Barakat, S.; Labialle, S.; Michaud, M.; Cogne, S.; Mazane, A.; Coleman, A. W.; Rigal, D.; Baggetto, L. G. Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells. Biochemstry 2005, 44, 4499-4509.
21. Troost, J.; Albermann, N.; Haefeli, W. E.; Weiss, J. Cholesterol modulates P-glycoprotein activity in human peripheral blood mononuclear cells. Biochem. Biophys. Res. Commun. 2004, 316, 705-711.
22. Troost, J.; Lindenmaier, N.; Haefeli, W. E.; Weiss, J. Modulation of cellular cholesterol alters P-glycoprotein activity in multidrugresistant cells. Mol. Pharmacol. 2004, 66, 1332-1339.
23. Rodriguez-Boulan, E.; Kreitzer, G.; Musch, A. Organization of vesicular trafficking in epithelia. Nat. Rev. 2005, 6, 233-246.
24. Bradbury, N. A.; Cohn, J. A.; Venglarik, C. J.; Bridges, R. J. Biochemical and biophysical identification of cystic fibrosis transmembrane conductance regulator chloride channels as components of endocytic clathrin-coated vesicles. J. Biol. Chem. 1994, 269, 8296-8302.
25. Lukacs, G. L., Segal, G.; Kartner, N.; Grinstein, S.; Zhang, F. Constitutive internalization of cystic fibrosis transmembrane conductance regulator occurs via clathrin-dependent endocytosis and is regulated by protein phosphorylation. Biochem. J. 1997, 328, 353-361.
26. Prince, L. S.; Peter, K.; Hatton, S. R.; Zaliauskiene, L.; Cotlin, L. F.; Clancy, J. P.; Marchase, R. B.; Collawn, J. F. Efficient endocytosis of the cystic fibrosis transmembrane conductance regulator requires a tyrosine-based signal. J. Biol. Chem. 1999, 274, 3602-3609.
27. Cheng, J.; Wang, H.; Guggino, W. B. Modulation of mature cystic fibrosis transmembrane regulator protein by the PDZ domain protein CAL. J. Biol. Chem. 2004, 279, 1892-1898.
28. Mohrmann, K.; van Eijndhoven, M. A.; Schinkel, A. H.; Schellens, J. H. Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). Cancer Chemother. Pharmacol. 2005, 56, 344-350.
29. Ozvegy, C.; Litman, T.; Szakacs, G.; Nagy, Z.; Bates, S.; Váradia, A.; Sarkadi, B. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem. Biophys. Res. Commun. 2001, 285, 111-17.
30. Diop N. K.; Hrycyna C. A. N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane. Biochemistry 2005, 44, 5420-5429.
31. Wakabayashi-Nakao, K.; Tamura, A.; Furukawa, T.; Nakagawa, H.; Ishikawa, T.; Quality control of human ABCG2 protein in the endoplasmic reticulum: Ubiquitination and proteasomal degradation. Adv. Drug Deliv. Rev. 2008, Dec 11. Epub ahead of print.
32. Gribar, J. J.; Ramachandra, M.; Hrycyna, C. A.; Dey, S.; Ambudkar, S. V.; Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system. J. Membr. Biol. 2000, 173, 203-214.
33. Schinkel, A. H.; Kemp, S.; Dolle, M.; Rudenko, G.; Wagenaar, E. N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J. Biol. Chem. 1993, 268, 7474-7481.
34. Germann, U. A.; Chambers, T. C.; Ambudkar, S. V.; Licht, T.; Cardarelli, C. O.; Pastan, I.; Gottesman, M. M. Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J. Biol. Chem. 1996, 271, 1708-1716.
35. Goodfellow, H. R.; Sardini, A.; Ruetz, S.; Callaghan, R.; Gros, P.; McNaughton, P. A.; Higgins, C. F. Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein. J. Biol. Chem. 1996, 271, 13668-13674.
36. Hegedus, T.; Sessler, T.; Scott, R.; Thelin, W.; Bakos, E.; Varadi, A.; Szabo, K.; Homolya, L.; Milgram, SL.; Sarkadi, B. C-terminal phosphorylation of MRP2 modulates its interaction with PDZ proteins. Biochem. Biophys. Res. Commun. 2003, 302, 454-461.
37. Szabo, K.; Bakos, E.; Welker, E.; Muller, M.; Goodfellow, H. R.; Higgins, C. F.; Varadi, A.; Sarkadi, B. Phosphorylation site mutations in the human multidrug transporter modulate its drug-stimulated ATPase activity. J. Biol. Chem. 1997, 272, 23165-23171.
38. Xie, Y.; Xu, K.; Linn, D. E.; Yang, X.; Guo, Z.; Shimelis, H.; Nakanishi, T.; Ross, D. D.; Chen, H.; Fazli, L.; Gleave, M. E.; Qiu, Y. The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J. Biol. Chem. 2008, 283(6), 3349-3356.
39. Ifergan, I.; Shafran, A.; Jansen, G.; Hooijberg, J. H.; Scheffer, G.L.; Assaraf, Y. G. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression a role for Bcrp in cellular folate homeostasis. J. Biol. Chem. 2004, 279(24), 25527-25534.
40. Ifergan, I.; Jansen, G.; Assaraf, Y. G. Cytoplasmic confinement of breast cancer resistance protein (BCRP/ABCG2) as a novel mechanism of adaptation to short-term folate deprivation. Mol. Pharmacol. 2005, 67(4), 1349-1359.
41. Ifergan, I.; Scheffer, G. L.; Assaraf, Y. G. Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance. Cancer Res. 2005, 65(23), 10952-10958.
42. Ugi, S.; Imamura, T.; Maegawa, H.; Egawa, K.; Yoshizaki, T.; Shi, K.; Obata, T.; Ebina, Y.; Kashiwagi, A.; Olefsky, J. M. Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3- L1 adipocytes. Mol. Cell. Biol. 2004, 24 (19), 8778-8789.
43. Misra, S.; Ujhazy, P.; Gatmaitan, Z.; Varticovski, L.; Arias, I. M. The role of phosphoinositide 3-kinase in taurocholateinduced trafficking of ATP-dependent canalicular transporters in rat liver. J. Biol. Chem. 1998, 273, 26638-44.
44. Takada, T.; Suzuki, H.; Gotoh, Y.; Sugiyama, Y. Regulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cells. Drug Metab. Dispos. 2005, 33, 905-909.
45. Mogi, M.; Yang, J.; Lambert, J. F.; Colvin, G. A.; Shiojima, I.; Skurk, C.; Summer, R.; Fine, A.; Quesenberry, P. J.; Walsh, K. Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J. Biol. Chem. 2003, 278(40), 39068-75.
46. Chu, T. S.; Chen, J. S.; Lopez, J. P.; Pardo, F. S.; Aguilera, J.; Ongkeko, W. M. Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squmous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 2008, 134(9), 979-84.
47. Misra, S.; Varticovski, L.; Arias, I. M. Mechanisms by which cAMP increases bile acid secretion in rat liver and canalicular membrane vesicles. Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 285, G316-24.
48. Lemos, C.; Jansen, G.; Peters, G. J. Drug transporters: Recent advances concerning BCRP and tyrosine kinase inhibitors. Br. J. Cancer 2008, 98(5), 857-62.
49. Ludescher, C.; Pall, G.; Irschick, E. U.; Gasti, G. Differential activity of P-glycoprotein in normal blood lymphocyte subset. Br. J. Haematol. 1998, 101, 722-727.
50. Chen, C. J.; Chin, J. E.; Ueda, K.; Clark, D. P.; Pastan, I.; Gottesman, M. M.; Roninson, I. B. Internal duplication and homology with bacterial transport proteins in the mdr1 (p-glycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47, 381-389.
51. 580 multi-drug-resistant human osteosarcoma cells. J. Submicrosc. Cytol. Pathol. 1996, 28, 93-100.
52. Willingham, M. C.; Richer, N. D.; Cornwell, M. M.; Tsuruo, T.; Hamada, H.; Gotesman, M. M.; Pastan, I. H. Immunochemical localization of P170 at the plasma membrane of multidrug-resistant human cells. J. Histochem. Cytochem. 1987, 35, 1451-1456.
53. Larsen, A. K.; Escargueil, A. E.; Skladanowski, A. Resistance mechanism associated with altered intracellular distribution of anticancer agents. Pharmacol. Ther. 2000, 85, 217-229.
54. Arancia, G.; Molinari, A.; Calcabrini, A.; Meschini, S.; Cianfruglia, M. Intracellular P-glycoprotein in multidrug resistance tumor cells. Ital. J. Anat. Embryol. 2001, 106, 59-68.
55. Fu, D.; Bebawy, M.; Kable, E. P.; Roufogalis, B. D. Dynamic and intracellular traffiking of P-glycoprotein-EGFP fusion protein: implication in multidrug resistance in cancer. Int. J. Cancer 2004, 109, 174-181.
56. Labroille, G.; Belloc, F.; Bilhou-Nabera, C.; Bonnefille, S.; Bascans, E.; Boisseau, M. R.; Bernard, P.; Lacombe, F. Cytometric study of intracellular P-gp expression and reversal of drug resistance. Cytometry 1998, 32, 86-94.
57. Solazzo, M.; Fantappiè, O.; Lasagna, N.; Sassoli, C.; Nosib, D.; Mazzantia, R. P-gp localization in mitochondria and its functional characterization in multiple drug-resistant cell lines. Exp. Cell Res. 2006, 312, 4070-4078.
58. Maraldi, N. M.; Zini, N.; Santi, S.; Scotlandi, K.; Serra, M.; Baldini, N. P-glycoprotein subcellular localization and cell morphocyte in MDR1 gene-transfected human osteosarcoma cell. Biol. Cell 1999, 9, 17-28.
59. Apodaca, G. Endocytic traffic in polarized epithelial cells: Role of the actin and microtubule cytoskeleton. Traffic 2001, 2, 149-159.
60. Rothman, J. E.; Wieland, F. T. Protein sorting by transport vesicles. Science 1996, 272, 227-234.
61. Mellman, I.; Warren, G. The road taken: Past and future foundations of membrane traffic. Cell 2000, 100, 99-112.
62. Geelson, P. A. Targeting of proteins to the Golgi apparatus. Histochem. Cell. Biol. 1998, 109, 517-32.
63. Fu, D.; Roufogalis, B. D. Actin disruption inhibits endosomal traffic of p-glycoprotein-EGFP and resistance to daunorubicin accumulation. Am. J. Physiol. Cell Physiol. 2007, 292, C1543-C1552.
64. Zerial, M.; McBride, H. Rab proteins as membrane organizers. Nat. Rev. Mol. Cell Biol. 2001, 2, 107-117.
65. Novick, P.; Zerial, M. The diversity of Rab proteins in vesicle transport. Curr. Opin. Cell Biol. 1997, 9, 496-504.
66. Olkkonen, V. M.; Stenmark, H. Role of Rab GTPases in membrane traffic. Int. Rev. Cytol. 1997, 176, 1-85.
67. Rodman, J. S.; Wandinger-Ness, A. Rab GTPases coordinate endocytosis. J. Cell Sci. 2000, 113(2), 183-192.
68. Jordens, I.; Marsman, M.; Kuijl, C.; Neefjes, J. Rab proteins, connecting transport and vesicle fusion. Traffic 2005, 6, 1070-1077.
69. Fu, D.; van Dam, E. M.; Brymora, A.; Duggin, I. G.; Robinson, P. J.; Roufogalis, B. D. The small GTPases Rab5 and RalA regulate intracellular traffic of P-glycoprotein. Biochim. Biophys. Acta 2007, 1773, 1062-1072.
70. Turim, M. J.; Adachi, R.; Hoffenberg, S.; Dickey, B. F. Traffic control: Rab GTPase and regulation of interorganellar transport. News Physiol. Sci. 2001, 16, 56-61.
71. Luciani, F.; Molinari, A.; Lozupone, F.; Calcabrini, A.; Lugini, L.; Stringaro, A.; Puddu, P.; Arancia, G.; Cianfriglia, M.; Fais, S. Pglycoprotein-actin association through ERM family proteins: A role in P-glycoprotein function in human cells of lymphoid origin. Blood 2002, 99, 641-648.
72. Bichat, F.; Mouawad, R.; Solis-Recendez, G.; Khayat, D.; Bastian, G. Cytoskeleton alteration in MCF7R cell, a multidrug resistant human breast cancer cell line. Anticancer Res. 1997, 17, 3393-3402.
73. Akeishita, H.; Kusuzaki, K.; Ashihara, T.; Gebhardt, M. C.; Mankin, H. J.; Hirasawa, Y. Actin organization associated with the expression of multidrug resistant phenotype in osteosarcoma cells and the effect of actin depolymerization on drug resistance. Cancer Lett. 1998, 126, 75-81.
74. Bretscher, A. Regulation of cortical structure by the ezrinradixinmoesin protein family. Curr. Opin. Cell Biol. 1999, 11, 109-116.
75. Denker, S. P.; Barber, D. L. Ion transport proteins anchor and regulate the cytoskeleton. Curr. Opin. Cell Biol. 2002, 14, 214-220.
76. Mangeat, P.; Roy, C, Martin. M. ERM proteins in cell adhesion and membrane dynamics. Trends Cell Biol. 1999, 9, 187-192.
77. Drubin, D. G.; Nelson, W. J. Origins of cell polarity. Cell 1996, 84, 335-344.
78. Doublier, S.; Riganti, C.; Voena, C.; Costamagna, C.; Aldieri, E.; Pescarmona, G.; Ghio, D.; Bosia, A. RhoA silencing reverts the resistance to doxorubicin in human colon cancer cells. Mol. Cancer Res. 2008, 6(10), 1607-1620.
79. Bacso, Z.; Nagy, H.; Goda, K.; Bene, L.; Fenyvesi, F.; Matko, J.; Szabo, G. Raft and cytoskeleton associations of an ABC transporter: P-glycoprotein. Cytometry A. 2004, 61(2), 105-16.
80. Petriz, J.; Gottesman, M. M.; Aran, J, M. An MDR-EGFP gene fusion allows for direct cellular localization, function and stability assessment of P-glycoprotein. Curr. Drug Deliv. 2004, 1(1), 43-56.
81. Cole, S. P.; Bhardwaj, G.; Gerlach, J. H.; Mackie, J. E.; Grant, C. E.; Almquist, K. C.; Stewart, A. J.; Kurz, E. U.; Duncan, A. M.; Deeley, R. G. Overexpression of a transporter gene in a multidrugresistant human lung cancer cell line. Science (NewYork), 1992, 258, 1650-1654.
82. Zaman, M. J., van der Valk, G. J., Izquierdo, P.; Schroeijers, M. A.; Scheffer, A. B.; van der Groep, G. L.; de Haas, P.; Meijer, C. M.; Scheper, C. J. Tissue distribution of the multidrug resistance protein. Am. J. Pathol. 1996, 148, 1237-1247.
83. Almquist, K. C.; Loe, D. W.; Hipfner, D. R.; Mackie, J. E.; Cole, S. P.; Deeley, R. G. Characterization of the M(r) 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cell. Cancer Res. 1995, 55, 102-110.
84. Cole, S. P.; Sparks, E.; Fraser, K.; Loe, D. W.; Grant, C. E.; Wilson, G. M.; Deeley, R.G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994, 54, 5902-5910.
85. Zaman, G. J.; Flens, M. J.; van Leusden, M. R.; de Haaas, M.; Mulder, H. S.; Lankelma, J.; Pinedo, H. M.; Scheper, R. J.; Baas, F.; Broxterman, H. J.; Borst, P. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. USA 1994, 91, 8822-8826.
86. Marquardt, D.; Center, M. S. Drug transport mechanisms in HL60 cells isolated for resistance to Adriamycin: Evidence for nuclear drug accumulation and redistribution in resistant cells. Cancer Res. 1992, 52, 3157-3163.
87. Krishnamachary, N.; Center, M. S. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res. 1993, 53, 3658-3661.
88. Flens, M. J.; Izquierdo, M. A.; Scheffer, G. L.; Fritz, J. M.; Meijer, C. J.; Scheper, R. J.; Zaman, G. J. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrugresistant tumor cells by monoclonal antibodies. Cancer Res. 1994, 54, 4557-4563.
89. van Luyn, M. J.; Muller, M.; Renes, J.; Meijer, C.; Scheper, R. J.; Nienhuis, E. F.; Mulder, N. H.; Jansen, P. L.; De Vries, E. G. Transport of glutathione conjugates into secretory vesicles is mediated by the multidrug-resistance protein 1. Int. J. Cancer 1998, 76, 55-62.
90. Hipfner, D. R.; Almquist, K. C.; Leslie, E. M.; Gerlach, J. H.; Grant, C. E.; Deeley, R. G.; Cole, S. P. Membrane topology of the multidrug resistance protein (MRP): A study of glycosylation-site mutants reveals an extracytosolic NH2 terminus. J. Biol. Chem. 1997 272(38), 23623-30.
91. Tusnády, G. E.; Bakos, E.; Varadi, A.; Sarkadi, B. Membrane topology distinguishes a subfamily of the ATP-binding cassette (ABC) transporters. FEBS Lett. 1997, 402(1), 1-3.
92. Bakos, E.; Evers, R.; Szakacs, G.; Tusnady, G. E.; Welker, E.; Szabo, K.; de Haas, M.; van Deemter, L.; Borst, P.; Varadi, A.; Sarkadi. Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J. Biol. Chem. 1998, 273, 32167-32175.
93. Westlake, C. J.; Qian, Y. M.; Gao, M.; Vasa, M.; Cole, S. P.; Deeley, R. G. Identification of the structural and functional boundaries of the multidrug resistance protein 1 cytoplasmic loop 3. Biochemistry 2003, 42, 14099-14113.
94. Westlake, C. J.; Cole, S. P.; Deeley, R. G. Role of the NH2-terminal membrane spanning domain of multidrug resistance protein 1/ABCC1 in protein processing and trafficking. Mol. Biol. Cell. 2005, 16, 2483-2492.
95. Westlake, C, J; Payen, L.; Gao, M.; Cole, S. P.; Deeley, R. G. Identification and Characterization of Functionally Important Elements in the Multidrug Resistance Protein 1COOH-terminal Region. J. Biol. Chem. 2004, 279(51), 53571-53583.
96. Imai, Y.; Nakane, M.; Kage, K.; Tsukahara, S.; Ishikawa, E.; Tsuruo, T.; Miki, Y.; Sugimoto, Y. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther. 2002, 1,611-616.
97. Kondo, C.; Suzuki, H.; Itoda, M.; Ozawa, S.; Sawada, J.; Kobayashi, D.; Ieiri, I.; Mine, K.; Ohtsubo, K.; Sugiyama, Y. Functional analysis of SNPs variants of BCRP/ABCG2. Pharm. Res. 2004, 21, 1895-1903.
98. Tamura, A.; Wakabayashi, K.; Onishi, Y.; Takeda, M.; Ikegami, Y.; Sawada, S.; Tsuji, M.; Matsuda, Y.; Ishikawa, T. Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci. 2007, 98, 231-239.
99. Morisaki, K.; Robey, R. W.; Ozvegy-Laczka, C.; Honjo, Y.; Polgar, O.; Steadman, K.; Sarkadi, B.; Bates, S. E. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother. Pharmacol. 2005, 56, 161-172.
100. Zamber, C. P.; Lamba, J. K.; Yasuda, K.; Farnum, J.; Thummel, K.; Schuetz, J. D.; Schuetz, E. G. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 2003, 13, 19-28.
101. Mizuarai, S.; Aozasa, N.; Kotani, H. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int. J. Cancer 2004, 109, 238-246.
102. Cusatis, G.; Gregorc, V.; Li, J.; Spreafico, A.; Ingersoll, R. G.; Verweij, J.; Ludovini, V.; Villa, E.; Hidalgo, M.; Sparreboom, A.; Baker, S. D. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J. Natl. Cancer Inst. 2006, 98, 1739-1742.
103. Sparreboom, A.; Gelderblom, H.; Marsh, S.; Ahluwalia, R.; Obach, R.; Principe, P.; Twelves, C.; Verweij, J. McLeod, H. L. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin. Pharmacol. Ther. 2004, 76, 38-44.
104. Gardner, E. R.; Burger, H.; van Schaik, R. H.; van Oosterom, A. T.; de Bruijn, E. A.; Guetens, G.; Prenen, H.; de Jong, F. A.; Baker, S. D.; Bates, S. E.; Figg, W. D.; Verweij, J.; Sparreboom, A.; Nooter, K. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin. Pharmacol. Ther. 2006, 80, 192-201.
105. de Jong, F. A.; Marsh, S.; Mathijssen, R. H.; King, C.; Verweij, J.; Sparreboom, A.; McLeod, H. L. ABCG2 pharmacogenetics: Ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin. Cancer Res. 2004, 10, 5889-5894.
106. Lee, S. S.; Jeong, H. E.; Yi, J. M.; Jung, H. J.; Jang, J. E.; Kim, E. Y.; Lee, S. J. & Shin, J. G. Identification and functional assessment of BCRP polymorphisms in a Korean population. Drug Metab. Dispos. 2007, 35, 623-632.
107. Poonkuzhali, B.; Lamba, J.; Strom, S.; Sparreboom, A.; Thummel, K.; Watkins, P.; Schuetz, E. Association of breast cancer resistance protein/ ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms. Drug Metab. Dispos. 2008, 36, 780-795.
108. Sparreboom, A.; Danesi, R.; Ando, Y.; Chan, J.; Figg, W. D. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist. Updat. 2003, 6, 71-84.
109. Sakaeda, T. MDR1 genotype-related pharmacokinetics: Fact or fiction? Drug Metab. Pharmacokinet. 2005, 20, 391-414.
110. Cascorbi, I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. 2006, 112, 457-473.
111. Hoffmeyer, S.; Burk, O.; von, R. O.; Arnold, H. P.; Brockmoller, J.; Johne, A.; Cascorbi, I.; Gerloff, T.; Roots, I.; Eichelbaum, M.; Brinkmann, U. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 2000, 97, 3473-3478.
112. Sauna, Z. E.; Kimchi-Sarfaty, C.; Ambudkar, S. V.; Gottesman, M. M. Silent polymorphisms speak: How they affect pharmacogenomics and the treatment of cancer. Cancer Res. 2007, 67, 9609-9612.
113. Kimchi-Sarfaty, C.; Gribar, J. J.; Gottesman, M. M. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol. Pharmacol. 2002, 62, 1-6.
114. Woodahl, E. L.; Yang, Z.; Bui, T.; Shen, D. D.; Ho, R. J. Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein. J. Pharmacol. Exp. Ther. 2004, 310, 1199-1207.
115. Conseil, G.; Deeley, R. G.; Cole, S. P. Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet. Genomics 2005, 15, 523-533.
116. Leslie, E. M.; Letourneau, I. J.; Deeley, R. G.; Cole, S. P. Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ ABCC1). Biochemistry 2003, 42, 5214-5224.
117. Ito, S.; Ieiri, I.; Tanabe, M.; Suzuki, A.; Higuchi, S.; Otsubo, K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001, 11, 175-184.
118. Keitel, V.; Kartenbeck, J.; Nies, A. T.; Spring, H.; Brom, M.; Keppler, D. Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome. Hepatology 2000, 32, 1317-1328.
119. Hashimoto, K.; Uchiumi, T.; Konno, T.; Ebihara, T.; Nakamura, T.; Wada, M.; Sakisaka, S.; Maniwa, F.; Amachi, T.; Ueda, K. Kuwano, M. Trafficking and functional defects by mutations of the ATP-binding domains in MRP2 in patients with Dubin-Johnson syndrome. Hepatology 2002, 36, 1236-1245.
120. Mor-Cohen, R.; Zivelin, A.; Rosenberg, N.; Shani, M.; Muallem, S.; Seligsohn, U. Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome. J. Biol. Chem. 2001, 276, 36923-36930.
121. Keitel, V.; Nies, A. T.; Brom, M.; Hummel-Eisenbeiss, J.; Spring, H.; Keppler, D. A common Dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2). Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 284, G165-G174.
122. Hirouchi, M.; Suzuki, H.; Itoda, M.; Ozawa, S.; Sawada, J.; Ieiri, I.; Ohtsubo, K.; Sugiyama, Y. Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharm. Res. 2004, 21, 742-748.